Oncology Biotech Company
IGF Oncology is a biotech company developing targeted anti-cancer drugs with better efficacy and lower side effects compared to existing chemotherapy treatments. Our lead drug, IGF-MTX, targets the deadly blood cancer MDS, and is currently in clinical trials at the Mayo Clinic, and the results so far are very promising.
Our mission isn’t merely to become a leader among oncology biotech companies. We want to save lives and reduce the suffering of cancer patients. We are developing new cancer drugs that are not only more effective than existing drugs but also have reduced side effects by having less toxicity to healthy cells.
By targeting IGF-1 receptors on malignant cancer cells, IGF Oncology is developing groundbreaking cancer treatments that can help physicians seek and destroy the most dangerous and aggressive cancer cells.
Oncology biotech companies are popping up all over the world, but there are no other oncology biotech companies like IGF Oncology. Company Founder and President Dr. Hugh McTavish is both a practicing patent attorney and a Ph.D. biochemist with extensive laboratory experience. He is a cancer survivor himself, and he knows first-hand how horrible chemotherapy can be. Now, he is dedicated to finding better, more effective anti-cancer drugs.
We are conducting a Phase 1b/2a clinical trial of our lead drug candidate — IGF-methotrexate – at the Mayo Clinic in patients suffering from a deadly blood cancer called myelodysplastic syndrome (MDS).
IGF Oncology, LLC, is a Minnesota company registered in Delaware.